TOKYO -- Having stumbled in one international acquisition, Daiichi Sankyo is again sharpening its focus outside Japan, with the goal of earning more than half of its revenues abroad as soon as the first half of 2020.
In fiscal 2016, Daiichi Sankyo generated just 39% of its sales abroad -- the lowest ratio among five major drugmakers in Japan. With sluggish growth in the domestic market, however, the company will step up its efforts to cultivate overseas customers, with a focus on the growth field of cancer drugs.
